Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1160 in Metastatic RCC, NPC, or Advanced NHL
NCT05721222Phase 2Terminated
- Sponsor
- Genmab
- Start
- Mar 2023
- Primary completion
- Nov 2025
- Countries
- 2
01
Overview
A Phase 2 trial of gen1160 in renal cell carcinoma (RCC), nasopharyngeal carcinoma (NPC), non-Hodgkin lymphoma (NHL), sponsored by Genmab. Started Mar 2023; status: terminated.
02
Drugs
gen1160
03
Conditions
renal cell carcinoma (RCC)nasopharyngeal carcinoma (NPC)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05721222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05721222.